1. Home
  2. ROCL vs IOBT Comparison

ROCL vs IOBT Comparison

Compare ROCL & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ROCL
  • IOBT
  • Stock Information
  • Founded
  • ROCL 2020
  • IOBT 2014
  • Country
  • ROCL United States
  • IOBT Denmark
  • Employees
  • ROCL N/A
  • IOBT N/A
  • Industry
  • ROCL Blank Checks
  • IOBT Biotechnology: Pharmaceutical Preparations
  • Sector
  • ROCL Finance
  • IOBT Health Care
  • Exchange
  • ROCL Nasdaq
  • IOBT Nasdaq
  • Market Cap
  • ROCL 55.7M
  • IOBT 56.7M
  • IPO Year
  • ROCL 2021
  • IOBT 2021
  • Fundamental
  • Price
  • ROCL $9.88
  • IOBT $0.77
  • Analyst Decision
  • ROCL
  • IOBT Strong Buy
  • Analyst Count
  • ROCL 0
  • IOBT 3
  • Target Price
  • ROCL N/A
  • IOBT $9.33
  • AVG Volume (30 Days)
  • ROCL 27.4K
  • IOBT 629.7K
  • Earning Date
  • ROCL 01-01-0001
  • IOBT 11-12-2024
  • Dividend Yield
  • ROCL N/A
  • IOBT N/A
  • EPS Growth
  • ROCL N/A
  • IOBT N/A
  • EPS
  • ROCL N/A
  • IOBT N/A
  • Revenue
  • ROCL N/A
  • IOBT N/A
  • Revenue This Year
  • ROCL N/A
  • IOBT N/A
  • Revenue Next Year
  • ROCL N/A
  • IOBT N/A
  • P/E Ratio
  • ROCL N/A
  • IOBT N/A
  • Revenue Growth
  • ROCL N/A
  • IOBT N/A
  • 52 Week Low
  • ROCL $9.85
  • IOBT $0.66
  • 52 Week High
  • ROCL $12.20
  • IOBT $2.10
  • Technical
  • Relative Strength Index (RSI)
  • ROCL 4.03
  • IOBT 39.04
  • Support Level
  • ROCL $9.85
  • IOBT $0.75
  • Resistance Level
  • ROCL $12.15
  • IOBT $0.84
  • Average True Range (ATR)
  • ROCL 0.31
  • IOBT 0.07
  • MACD
  • ROCL -1.15
  • IOBT 0.00
  • Stochastic Oscillator
  • ROCL 0.00
  • IOBT 13.79

About ROCL Roth CH Acquisition V Co.

Roth CH Acquisition V Co is a blank check company.

About IOBT IO Biotech Inc.

IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.

Share on Social Networks: